Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution
about
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Murine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptasePhenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analysesCrystal engineering of HIV-1 reverse transcriptase for structure-based drug designUnique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changesStructure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptaseSelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anIdentifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction networkStructure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.Tackling the challenges posed by target flexibility in drug design.Mutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme.Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug designSteered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymeraseProtein-protein interactions as targets for antiviral chemotherapy.In search of a selective antiviral chemotherapy.Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesisMolecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+.Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptaseExamining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybridsNew human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) mutants with increased fidelity of DNA synthesis. Accuracy, template binding, and processivity.Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C SubstitutionsComparison of second-strand transfer requirements and RNase H cleavages catalyzed by human immunodeficiency virus type 1 reverse transcriptase (RT) and E478Q RT.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.Synthesis of Pyrazine-1,3-thiazine Hybrid Analogues as Antiviral Agent Against HIV-1, Influenza A (H1N1), Enterovirus 71 (EV71), and Coxsackievirus B3 (CVB3).Cystatins in health and disease.A check on rational drug design: molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase.Design, synthesis, and biological evaluation of novel 2H-pyran-2-one derivatives as potential HIV-1 reverse transcriptase inhibitors.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity.Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding.Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
P2860
Q24540388-FBC9B6DB-3108-4A83-A109-5C06419574B6Q24647519-4346A892-F118-43A7-BAB2-DE6C4B3224F8Q27621483-A87F4CB2-0F82-47DD-A81D-0D80066A308DQ27651402-DA4C3BA9-1749-4F4B-931E-81B945B82BC9Q27735940-7AFD19DF-2CF4-4218-A654-D5D238E7D3A0Q27764900-BE3ECD5D-CD77-48EE-B436-EEE520F6E1E1Q28369309-C7FC5947-7EF4-43F6-AB96-3F524B93D5E7Q28378760-329478E4-743F-40CF-90D4-9046D4E484EBQ28533728-94B65507-CE77-49F8-B893-42C38F6166C4Q30342229-03F60FBD-28DD-41A2-A5B8-9AA595BF8574Q30419540-83D24B75-0B62-4BB7-850D-25A3E515B0C3Q30658869-766232A0-0EC7-4471-963A-0DE11B64B616Q34053804-859BDBDD-9B15-4D67-9556-E14485A347B6Q34181367-EED2DB63-06C8-46C0-801E-324C5FD8092AQ34434926-C37554C2-317D-4E32-9577-AC8BDB7C9E6DQ34747522-035DB0FB-755E-482E-806D-394EA46BD30BQ35375912-6D898457-6929-47D4-9E15-0CF1E151B682Q35851936-A0F391E6-8199-4817-B977-049D4EA0D5C0Q35907177-F5B5F7A2-A0E6-4795-AD8D-83F665DCBFECQ36278914-EFCF0DAB-5749-4D9B-B0BB-FF2F2207E066Q36297904-02EBC198-D0A7-404F-850C-036367E695A1Q36632128-59859563-A3BD-4863-8EE4-38C9D22B1E66Q36718302-8B5DCEDE-901B-47CE-BD31-451C4487ECB6Q36810415-38A3C453-FA65-43E4-BBD2-3CAA427875AAQ36890771-6BB118C1-ABA7-419B-AEA4-4AAA8C66D6E1Q38320544-2C89F1C2-B1C9-457B-B799-ED3214083080Q38587299-0C6F2F6B-9775-49CC-82E1-63A9F6A719BEQ39350740-9DB9F607-7971-4347-B2DD-BA8823A6A065Q39593409-F2B130F0-A276-47D1-B8AB-EA481827E0BFQ39699409-3184CEC1-7138-456B-B68D-56F893A5AC41Q39912641-F7623BE8-5E7A-4B58-8A07-18AA36640759Q40060575-A3A62451-DC3B-4BE1-9FEC-4532043A760AQ40721270-4714324D-2C15-4C81-8B81-FBC1C617580BQ41161690-F6D48243-AE82-4270-92F0-A3CC12557E68Q41452204-7F6C88EF-F6F6-4977-9E08-2CF10005F6D3Q41591513-4A1B7DE4-2B6F-4068-BE94-899D0531F052Q41879018-9B28722A-0196-493B-B7B4-0F73E03B6998Q43516121-2783C386-5E53-4A72-A8C4-AF5A88B17EE6Q43557768-A41417A7-AE95-48E0-8C8C-938571C153B0Q44195803-0282D41F-3CFD-45FC-966B-E095F6BADF1F
P2860
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@ast
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@en
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@nl
type
label
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@ast
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@en
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@nl
prefLabel
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@ast
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@en
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@nl
P2093
P3181
P1433
P1476
Structure of HIV-1 reverse tra ...... PA R 95845 at 2.8 A resolution
@en
P2093
A Jacobo-Molina
C Tantillo
P304
P3181
P356
10.1016/S0969-2126(01)00168-X
P50
P577
1995-04-01T00:00:00Z